Results 131 to 140 of about 590,194 (288)

Meningococcal vaccine and herd immunity [PDF]

, 2000
Achille Gikas, John Pediaditis, Yannis Tselentis   +2 more
openalex   +3 more sources

The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy

Expert Opinion on Biological Therapy, 2015
Introduction: Capsular group B meningococcal disease is a leading cause of childhood meningitis and septicaemia. Up to 10% of sufferers die, and sequelae remain in > 30% of survivors.
C. Rollier, C. Dold, L. Marsay, M. Sadarangani, A. Pollard   +4 more
semanticscholar   +1 more source

Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs

BMC Public Health, 2020
Background Monovalent meningococcal C conjugate vaccine (MCCV) was introduced into the routine immunization program in many countries in Europe and worldwide following the emergence of meningococcal serogroup C (MenC) in the late 1990s.
Myint Tin Tin Htar, Sally Jackson, Paul Balmer, Lidia Cristina Serra, Andrew Vyse, Mary Slack, Margarita Riera-Montes, David L. Swerdlow, Jamie Findlow   +8 more
doaj   +1 more source

Meningococcal vaccines.

Current opinion in investigational drugs (London, England : 2000), 2003
Neisseria meningitidis is one of the leading infectious causes of death in children under five years old in industrialized countries, and most cases can be attributed to five disease-causing serogroups: A, B, C, Y and W135. Meningococcal vaccine development began in the 1930s with killed whole-cell and exotoxin vaccines, but widespread use of ...
Collins, C, Pollard, A
openaire   +2 more sources

A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies

Journal of Infectious Diseases, 2018
BACKGROUND Meningococcal outer membrane vesicle (OMV) vaccines are prepared with detergents to remove endotoxin, which also remove desirable antigens such as factor H binding protein (FHbp).
P. Beernink, Emma Ispasanie, L. Lewis, S. Ram, G. Moe, D. Granoff   +5 more
semanticscholar   +1 more source

Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines [PDF]

, 1983
E. C. Beuvery, Frank Miedema, R. van Delft, J. Haverkamp   +3 more
openalex   +1 more source

Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges

Human Vaccines & Immunotherapeutics, 2018
Africa historically has had the highest incidence of meningococcal disease with high endemic rates and periodic epidemics. The meningitis belt, a region of sub-Saharan Africa extending from Senegal to Ethiopia, has experienced large, devastating ...
M. Mustapha, L. Harrison
semanticscholar   +1 more source

Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein [PDF]

, 1992
Peter van der Ley, Jan Poolman
openalex   +1 more source

Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps

Human Vaccines & Immunotherapeutics, 2018
The introduction of a new Group A meningococcal conjugate vaccine, MenAfriVacR, has been a important public health success. Group A meningococcal meningitis has disappeared in all countries where the new Men A conjugate vaccine has been used at public ...
F. Laforce, M. Djingarey, S. Viviani, M. Preziosi   +3 more
semanticscholar   +1 more source

Bioinformatics Analysis of Global Diversity in Meningococcal Vaccine Antigens over the Past 10 Years: Vaccine Efficacy Prognosis. [PDF]

Med Sci (Basel), 2023
Savitskaya VY, Dolinnaya NG, Strekalovskikh VV, Peskovatskova ES, Snyga VG, Trefilov VS, Monakhova MV, Kubareva EA.   +7 more
europepmc   +1 more source